Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Vera Therapeutics (NasdaqGM:VERA) with a ...

Wolfe Research initiated coverage of Vera Therapeutics (VERA) with an Outperform rating and $49 price target The firm is ...

After hours: February 3 at 5:26:14 PM EST Loading Chart for VERA ...

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) had its price target lifted by analysts at JPMorgan Chase & Co. from $51.00 to $53.00 in a research note issued to investors on ...

Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (IPO) filed by CAR-T ...

After hours: 31 January at 5:46:27 pm GMT-5 ...

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

R Squared Ltd bought a new position in shares of Incyte Co. (NASDAQ:INCY – Free Report) in the fourth quarter, ...

and Vera Therapeutics’ atacicept, which are already in phase 3 and so one to two years ahead in development. That said, they believe Alpine’s drug has best-in-class potential as a result of ...